CRDF (Cardiff Oncology, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Cardiff Oncology, Inc. Common Stock (CRDF) is a publicly traded Healthcare sector company. As of May 21, 2026, CRDF trades at $1.84 with a market cap of $115.55M and a P/E ratio of -1.95. CRDF moved +4.55% today. Year to date, CRDF is -35.21%; over the trailing twelve months it is -40.07%. Its 52-week range spans $1.48 to $5.64. Analyst consensus is strong buy with an average price target of $9.33. Rallies surfaces CRDF's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns CRDF stock?
Hedge funds tracked by Rallies that own CRDF include Orbimed Advisors. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cardiff Oncology, Inc. Common Stock.
CRDF Key Metrics
Key financial metrics for CRDF
Metric
Value
Price
$1.84
Market Cap
$115.55M
P/E Ratio
-1.95
EPS
$-0.93
Dividend Yield
0.00%
52-Week High
$5.64
52-Week Low
$1.48
Volume
0
Avg Volume
0
Revenue (TTM)
$488.00K
Net Income
$-41.44M
Gross Margin
0.00%
Top Hedge Funds Holding CRDF
Orbimed Advisors holds 573.88K shares of CRDF, changed -62.70% as of Mar 31, 2025.
Hedge funds tracked by Rallies that own CRDF include Orbimed Advisors. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cardiff Oncology, Inc. Common Stock.
Does Rallies show 13F holders for CRDF?
Yes. Rallies tracks hedge fund and 13F ownership data for CRDF, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CRDF research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CRDF. It does not provide personalized investment advice.
